Strategic Report Operational Detail Our prospects and targets for 2015 Various factors may cause differences between Indiviors expectations and actual results, including: factors affecting sales of Suboxone Indivior enters its first full year as an independent Company with Tablet, Suboxone Film, Subutex Tablet and any future products: confidence that its strategy and pipeline will deliver significant the outcome of research and development activities: decisions by value to Shareholders over time.
While the Company forecasts some regulatory authorities regarding the Groups drug applications: the compression in revenue and earnings in the next 12 to 24 months, speed with which regulatory authorizations, pricing approvals and with greater competitive pressure, Indivior believes that Suboxone product launches may be achieved: the outcome of post-approval Film will prove very resilient due to the loyalty of patients, physicians clinical trials: competitive developments: difficulties or delays in and payors, and to its demonstrated pharmaco-economic benefit.
manufacturing: the impact of existing and future legislation and Indivior remains the world-leading company that is committed to regulatory provisions on product exclusivity: trends toward managed developing better access to treatment and better patient outcomes care and healthcare cost containment: legislation or regulatory for those who suffer the chronic relapsing conditions of addiction.
action affecting pharmaceutical product pricing, reimbursement or access: claims and concerns that may arise regarding the safety Financial guidance or efficacy of the Groups products and product candidates: risks The prognosis for the market environment in 2015 outlined in the related to legal proceedings: the Groups ability to protect its patents prospectus last November remains unchanged.
In particular, the and other intellectual property: the outcome of the Suboxone Film outlook for 2015 is very uncertain as to the timing, extent and impact patent litigation relating to the three ongoing Abbreviated New Drug of tablet price erosion.
As a result, managements guidance, based on Application ANDA lawsuits: changes in governmental laws and internal forecasts, is for net revenue in a range of $850m-$880m and regulations: issues related to the outsourcing of certain operational net income in a range of $130m-$155m: however the outcome could and staff functions to third parties: uncertainties related to general be higher in a more positive environment or lower in a more adverse economic, political, business, industry, regulatory and market scenario.
All guidance is based on the current indicative all in cost conditions: and the impact of acquisitions, divestitures, restructurings, on the Companys borrowings of 7% to 8%, excluding exceptional internal reorganizations, product recalls and withdrawals and other items and at constant currency.
The Company will update the market unusual items.
Any forward-looking statements that we make in this annual report Cautionary note regarding forward-looking statements speak only as of the date of this annual report.
We assume no obligation to update our forward-looking statements whether as a This annual report contains forward-looking statements.
We may, result of new information, future events or otherwise, after the date in some cases, use terms such as predicts, believes, potential, of this annual report.
proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that By Order of the Board convey uncertainty of future events or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the future strategy and performance of the Group.
Lola Emetulu Company Secretary Indivior PLC 103-105 Bath Road Slough Berkshire SL1 3UH Company registration number: 9237894 March 27, 2015 Indivior Annual Report and Financial Statements 2014 31
